Editor: Prof. Tatjana Stopar Pintarič, MD, PhD, DEAA
Submission deadline: 31 December 2023
Editor: Dr. Marko Zdravkovic, MD, PhD
Submission deadline: 30 November 2022
Editor: Kyungwon Lee, MD, PhD,Young Duck Cho, MD, PhD
Submission deadline: 31 December 2022
Editor: Tomasz Kłosiewicz, MD, MSc,Mateusz Puślecki, PhD
Submission deadline: 31 December 2022
Editor: Dr. Ioanna Siafaka, MD, PhD,Dr. Maria Kokolaki, MD, PhD,Dr. Athina Vadalouca, MD, PhD, FIPP,Dr. Evmorfia Stavropoulou, MD, PhD, EDRA,Dr. Eleni Moka, MD, PhD, MSc, EDRA
Submission deadline: 27 May 2022
Editor: Prof. Won Young Kim, MD, PhD
Submission deadline: 01 June 2022
Editor: Lecturer dr. Constantin Munteanu, PhD,Prof. Dr. Gelu Onose,Associate Prof. Dr. Mariana Rotariu, PhD,Assistant Prof. Dr. Gabriela Dogaru, PhD,Associate Prof. Dr. Elena Valentiana IONESCU, PhD,Assistant Prof. Dr. Cristina Daia, PhD
Submission deadline: 31 March 2022
Editor: Dr. Giovanni Galeoto
Submission deadline: 10 December 2021
A summary of the editorial process is given in the flowchart below.
Signa Vitae Editorial Process
The following provides notes on each step.
Immediately after submission, a Preliminary review will first be carried out by the managing editor to assess if the submitted manuscript complies with the provided guidelines for preparation of articles. Articles that do not comply with the guidelines will be sent back to the authors. The relevant editor (usually the Editor-in-Chief/Editorial Board Member of a journal or the Guest Editor of a Special Issue) will then be notified of the submission and invited to perform a Pre-check. The relevant editors can decide to continue with the peer-review process, reject a manuscript, or request revisions before peer-review.
Signa Vitae (SV) requires that editorial staff or editors not be involved in processing their own academic work. The Editor or members of the Editorial Board may occasionally submit their own manuscripts for possible publication in the journal. In these cases, the peer review process will be managed by alternative members of the Board. Submissions will be assigned to at least two independent outside reviewers. The submitting Editor/Board member will have no involvement in the decision-making process. Decisions will be made by other Editorial Board Members who do not have a conflict of interest with the author.
Guest Editors should not hold conflicts of interest with authors whose work they are assessing (e.g., from the same institution or collaborate closely). In this case, the Editor-in-Chief or a suitable Editorial Board member will make the Pre-check and Final decisions for submitted papers.
Signa Vitae adopts double-blind peer review. Once a manuscript passes the initial checks, it will be assigned to at least two independent experts for peer-review. SV editors will check to make sure there are no conflicts of interest before contacting reviewers, and will not consider those with competing interests. Reviewers are asked to declare any conflicts of interest before reviewing any submitted manuscript.
In cases Minor revisions/Major revisions are recommended, the author is usually requested to revise the paper before referring to the the relevant editor (usually the Editor-in-Chief/Editorial Board Member of a journal or the Guest Editor of a Special Issue). Articles may or may not be sent to reviewers after minor revision, which depends on whether the reviewer requested to see the revised version or not. The revised manuscript after major revision will be sent back to reviewers again. We typically allow no more than two rounds of major revisions per manuscript. Any further revision needed will follow the decision of the relevant editors.
All reviewer comments should be responded point-by-point. Where the authors disagree with a reviewer, they must provide a clear response or rebuttal.
The acceptance of the manuscript will depend on the revisions made to the manuscript. Authors need to provide a point by point response or a rebuttal if some of the reviewer’s comments cannot be revised. The Acceptance or rejection decision will be made by the relevant editor (usually the Editor-in-Chief/Editorial Board Member of a journal or the Guest Editor of a Special Issue) after peer review, and the editor can select from the following options: Accept in Present Form, Accept after Minor Revisions, Reconsider after Major Revisions, Reject.
(In some instances, the relevant editor may support a decision of manuscript acceptance despite a reviewer recommendation to reject. Journal staff will seek a second independent opinion from an Editorial Board member or the Editor-in-Chief before communicating a final decision to the authors.)
Authors may appeal a rejection judgement by sending an e-mail to the journal’s Editorial Office. The appeal must provide a detailed justification, including point-by-point responses to the reviewers' and/or Editor's comments. The Managing Editor of the journal will forward the manuscript and related information (including the identities of the referees) to the Editor-in-Chief, Associate Editor, or Editorial Board member. The Editor being consulted will subsequently be asked to provide an advisory recommendation on the manuscript and may recommend acceptance, further peer-review, or uphold the original rejection decision. A reject decision at this stage is final and cannot be reversed.
SV carries out production on all manuscripts, including copy editing, layout and conversion to XML. Language editing is carried out by professional English editing editors. We recommend authors use Englishgo’s English editing service prior to publication or during revisions. If you have used an alternative service, please provide a copy certificate to the Editorial Office.
The submitted, accepted and published dates will be shown in the PDF and XML files of the published articles, a digital object identifier (DOI) number will also be assigned for each published article. The submitted date is the date on which the editors received the original (or if previously rejected, the resubmitted) manuscript. The accepted date is when the editor sends the acceptance letter. The published date is the earliest date that the final version-of-record is made available on the publisher's website.
SV follows the following guidelines and standards. Submission of a manuscript to Signa Vitae implies that all authors have read and agreed to its content, and the manuscript conforms to the journal’s policies.
ICMJE: Medically related SV follows the recommendations of the International Committee of Medical Journal Editors. The guidelines comprehensively cover all aspects of editing, from how the journal is managed to details about peer review and handling complaints.
PRISMA covers systematic reviews and meta-analyses of interventional studies and MOOSE for systematic reviews and meta-analyses of observational studies. Authors are recommended to complete the checklist and flow diagram and include them with their submission.
CARE guideline (for CAse REports) was developed by an international group of experts to support an increase in the accuracy, transparency, and usefulness of case reports. View and download the CARE checklist.
Other related guidelines, please visit the equator network (https://www.equator-network.org/).
SV follows the guidelines of the Committee on Publication Ethics (COPE) and the International Committee of Medical Journal Editors (ICMJE) Recommendations for the Conduct, Reporting, Editing and Publication of Scholarly Work in Medical Journals.
SV follows COPE’s procedures for dealing with potentially unethical behavior by authors, reviewers or editors. Our editorial staff are trained in how to detect and respond to potential ethical problems.
More information about our Publishing Ethics policy.
Editorial independence dictates that decision to accept or reject a manuscript is based on the scientific merit of the article but not to any other relations for example pressure from the publisher to the journal editor. This means that Editor is independent in his/her decision and will not be under pressure of any influential body or organization.
Our editorial policy is consistent with the principles of editorial independence presented by the World Association of Medical Editors (WAME).
Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,200 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.
Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.
Chemical Abstracts Service Source Index The CAS Source Index (CASSI) Search Tool is an online resource that can quickly identify or confirm journal titles and abbreviations for publications indexed by CAS since 1907, including serial and non-serial scientific and technical publications.
Index Copernicus The Index Copernicus International (ICI) Journals database’s is an international indexation database of scientific journals. It covered international scientific journals which divided into general information, contents of individual issues, detailed bibliography (references) sections for every publication, as well as full texts of publications in the form of attached files (optional). For now, there are more than 58,000 scientific journals registered at ICI.
Geneva Foundation for Medical Education and Research The Geneva Foundation for Medical Education and Research (GFMER) is a non-profit organization established in 2002 and it works in close collaboration with the World Health Organization (WHO). The overall objectives of the Foundation are to promote and develop health education and research programs.
Scopus: CiteScore 1.0 (2022) Scopus is Elsevier's abstract and citation database launched in 2004. Scopus covers nearly 36,377 titles (22,794 active titles and 13,583 Inactive titles) from approximately 11,678 publishers, of which 34,346 are peer-reviewed journals in top-level subject fields: life sciences, social sciences, physical sciences and health sciences.
Embase Embase (often styled EMBASE for Excerpta Medica dataBASE), produced by Elsevier, is a biomedical and pharmacological database of published literature designed to support information managers and pharmacovigilance in complying with the regulatory requirements of a licensed drug.